End-diastolic Volume Index Research Articles

Evaluation of advanced therapies in severe post-myocardial infarction ventricular dysfunction: a swine model study

Abstract Introduction Ejection fraction (EF) is an important predictor of cardiovascular morbidity and mortality after myocardial infarction (MI). Advanced therapies (specifically cardiosphere-derived cells-CDCs- or their secretome –S-CDCs) could be useful in this scenario. Our objective was to evaluate whether intracoronary (IC) administration of CDCs or S-CDCs could improve cardiac function in a porcine model of severe post-MI ventricular dysfunction. Methods A reperfused MI model was induced in Large White pigs. Animals with an EF<30% on day 7 post-MI received, in a blinded manner, 30x106 CDCs (n=7), 9.16 mg S-CDCs (n=6) or 5 ml of saline (n= 6) via IC route. Two magnetic resonance imaging studies were performed, on day 7 (to verify the inclusion criteria) and at 10 weeks, calculating: EF, indexed end systolic (ESVi) and diastolic (EDVi) volumes and infarct size. Results No significant differences in cardiac function were observed between the groups at 10 weeks. The S-CDCs group showed the best results in terms of cardiac function, with EF at 24±2% vs 29±3% vs 21±3%, EDVi at 104±8 ml/m² vs 95±8 ml/m² vs 107±9 ml/m², ESVi at 79±7 ml/m² vs 68±8 ml/m² vs 86±10 ml/m², and infarct size at 10±1% vs 11±2% vs 10±2% in the Control, S-CDCs, and CDCs groups, respectively. Conclusion In this experimental model of severe post-MI ventricular dysfunction, the administration of the assayed advanced therapies does not seem to be clinically advantageous, although the use of secretome could slightly improve overall ventricular function.

Sex differences in ventricular-vascular interactions associated with aerobic capacity

BackgroundAerobic capacity measured by maximal oxygen uptake (VO2max) is related to functional capacity and is a strong independent predictor of all-cause and disease-specific mortality. Sex-specific cardiac and vascular responses to endurance training have been observed, however, their relative contributions to VO2max are less understood. The purpose of this study was to evaluate sex-specific ventricular-vascular interactions associated with VO2max in healthy males and females.MethodsSixty-eight males and females (38% females, 35 ± 10y) characterised as recreational exercisers to highly trained endurance athletes, and free of chronic disease underwent a cycle ergometer to assess VO2max. Resting arterial compliance and echocardiographic evaluation of left ventricular (LV) structure and function were measured and indexed to body surface area.ResultsVO2max was similar between groups (54 ± 6 vs. 50 ± 7 ml/kg/min, p = 0.049). Indexed LV mass (LVMi) was higher (96 ± 15 vs. 81 ± 11, p = 0.001) in males versus females, respectively. Linear regression analysis revealed two models that were significantly associated with VO2max in males and females. In males, the two models included (1) longitudinal diastolic strain rate and LVMi (r2 = 0.31, p = 0.003) and (2) indexed end-diastolic volume (EDVi) and longitudinal diastolic strain rate (r2 = 0.34, p < 0.001). In females, the linear regression models included (1) LVMi, large arterial compliance, longitudinal systolic strain rate, and age (r2 = 0.69, p < 0.001) and (2) EDVi, large arterial compliance, longitudinal systolic strain rate, and age (r2 = 0.52, p = 0.003).ConclusionThese findings reveal that while in both sexes, LVMi and LVEDVi are associated with VO2max, arterial compliance was also found to contribute to the variance in VO2 max in females, but not in males. Further, ventricular relaxation was a significant factor in aerobic capacity in males, while in females ventricular contraction was a significant factor.

Comprehensive 4D-flow cardiac magnetic resonance evaluation of the descending thoracic aorta in aortic regurgitation.

To assess the reproducibility of 4D-Flow cardiac magnetic resonance (CMR) parameters in the descending thoracic aorta-DTAo-(regurgitant fraction [RF], end-diastolic reverse flow [EDRF], and holodiastolic flow reversal [HDR]), and the relationship with RF in the sinotubular junction (STJ), and the left ventricular end-diastolic volume index (LVEDVI) in patients with chronic aortic regurgitation (AR). A descriptive study of these variables was conducted. A receiver operating characteristic curve was used to determine the optimal cut-off point. Thirty patients had severe AR (RF ≥ 30%, STJ) and 60 mild-to-moderate (RF < 30%). The mean age was 59 ± 17 years. Left ventricular ejection fraction (LVEF) was 56% (53-61%) and LVEDVI was 94 (76-128) mL/m2. Flow in the DTAo at the left inferior pulmonary vein (LIPV) was easily identifiable and measurements were highly reproducible. The intraclass correlation coefficient was 0.969 (95% CI: 0.954-0.980) for RF and 0.929 (95% CI: 0.893-0.952) for EDRF. Flow parameters measured at the LIPV were all significantly greater in the severe AR group: RF (21% vs. 6%, P < 0.001), EDRF (20 vs. 4 mL/s; P < 0.001), and HDR (20% vs. 8%; P < 0.001). Three parameters-presence of HDR, RF ≥ 17%, and EDRF ≥ 7 mL/s at the LIPV-were associated with RF ≥ 30% in the STJ and elevated LVEDVI. 4D-flow CMR can reproducibly assess flow in the DTAo in patients with chronic AR. An RF ≥ 17%, EDRF ≥ 7 mL/s, and/or the presence of HDR in the DTAo (LIPV) were associated with an RF ≥ 30% in STJ and elevated LVEDVI.

Left ventricular elastance with resting volumetric transthoracic echocardiography identifies different phenotypes in heart failure with preserved ejection fraction: A retrospective analysis of a multicenter prospective observational study.

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity including patients with different phenotypes of near normal, normal, and supernormal left ventricular (LV) function. To assess the value of resting LV elastance (also known as force) with transthoracic echocardiography (TTE) to identify HFpEF phenotypes. In a prospective, observational, multicenter study, 2380 HFpEF patients were recruited from July 2016 to May 2024. Systolic blood pressure (SBP) was measured. We assessed LV end-diastolic volume (EDV), end-systolic volume (ESV), EF, force (SBP/ESV), stroke volume (SV), arterial elastance (AE), ventricular-arterial coupling (VAC), and left atrial volume index (LAVI). Global longitudinal strain (GLS) was available in 1164 (48.9%) patients. 680 patients finished follow-up with a composite end-point of major adverse cardiac events (MACEs). Patients were divided into three groups: low force (< 25th percentile, Group 1, < 3.24 mmHg/ml), intermediate force (≥ 25th percentile and ≤ 75 th percentile, Group 2, 3.24-5.48 mmHg/ml), and high force (> 75 th percentile, Group 3, >5.48 mmHg/ml). The 3 groups showed a gradient with descending values (Group 3>2>1) for SBP, EF, GLS, AE, and VAC, with the opposite gradient (Group 1> 2> 3) for EDV, ESV, SV, and LAVI values (all P<0.01). After a median follow-up of 16 months, 205 MACEs occurred in 138 patients. Cumulative MACEs rate was lowest in group 2 (14.7% person-year), higher in group 1 (16.1% person-year) and 3 (22.9% person-year, log rank p = 0.036). HFpEF patients present with different LV contractile phenotypes, easily identified with resting LV force and volumetric TTE. The dominant hemodynamic feature of hypocontractile phenotype is a preload recruitment with larger LV EDV and normal SV, while the hypercontractile phenotype is characterized by a small LV with reduced SV. The hypercontractile and hypocontractile phenotypes are associated with a higher risk of subsequent events.

A Protocol Investigation Comparing Transcatheter Repair with the Standard Surgical Procedure for Secondary Mitral Regurgitation.

Background: Secondary mitral regurgitation (SMR) is characterized by a pathological process impacting the left ventricle (LV) as opposed to the mitral valve (MV). In the absence of structural alterations to the MV, the expansion of the LV or impairment of the papillary muscles (PMs) may ensue. A number of technical procedures are accessible for the purpose of determining the optimal resolution for MR. Nevertheless, there is a dearth of rigorous data to facilitate a comparative analysis of MV replacement, MV repair (including subvalvular repair), and transcatheter mitral valve interventions (TMV-Is). The objective of this investigation is to evaluate and compare the efficacy and clinical outcomes of transcatheter mitral valve repair (TMV-r) utilizing the edge-to-edge mitral valve repair (TEER) procedure in comparison to conventional surgical mitral valve interventions (S-SMVis) in patients with secondary mitral regurgitation. Methods and analysis: A consortium of five cardiac surgery institutions from four European states and Japan have joined forces to establish a multicenter observational registry, designated TEERMISO. Patients who underwent technical procedures for SMR between January 2007 and December 2023 will be enrolled consecutively into the TEERMISO registry. The investigation team evaluated the comparative efficacy of replacement and repair techniques, utilizing both the standard surgical methodology and the transcatheter intervention. The primary clinical outcome will be the degree of left ventricular remodeling, as assessed by the left ventricular end-diastolic volume index, at 10 years. The forthcoming research will assess a variety of secondary endpoints, among which all-cause mortality will be the primary endpoint. Subsequent assessments will be made in the following order: functional status, hospitalization, neurocognition, physiological measures (echocardiographic assessment), occurrence of adverse clinical incidents, and reoperation. Ethics and dissemination: The multicenter design of the database is anticipated to reduce the potential for bias associated with institutional caseload and surgical experience. All participating centers possess an established mitral valve protocol that facilitates comprehensive follow-up and management of any delayed mitral complications following replacement surgery or surgical repair of the secondary mitral regurgitation. The data collected will provide insights into the impact of diverse surgical approaches on standard mitral valve surgery and TEER. This will facilitate the evaluation of LV remodeling over the course of long-term post-procedural follow-up. Trial Registration: ClinicalTrials.gov ID: NCT05090540; IRB ID: 202201143.

Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI).

Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are considered to be at risk of progressive adverse cardiac remodelling which can lead to the development of heart failure and death. The early addition of a sodium-glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients. We performed a randomized, double-blind, placebo-controlled, multicentre trial using cardiovascular magnetic resonance imaging (MRI), in patients with left ventricular systolic dysfunction following MI. Eligible patients were those ≥12 h and ≤14 days following acute MI, with an LVEF <45% by MRI. Patients were randomized to empagliflozin 10 mg once a day or matching placebo. The primary outcome was the change in left ventricular end-systolic volume indexed to body surface area (LVESVI) from baseline to 24 weeks. Secondary outcomes included measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and high-sensitivity troponin I (hs-TnI) and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) concentrations. From October 2022 to January 2024, 105 eligible patients were randomized. The mean age was 63 ± 11 years and 90 (87%) were male. The mean LVEF was 34.8 ± 6.0%. In the placebo group, LVESVI decreased by 7.8 ± 16.3 ml/m2, left ventricular end-diastolic volume index (LVEDVI) did not change (-0.3 ± 18.7 ml/m2) and LVEF increased by 8.5 ± 7.4% at 24 weeks from baseline. Empagliflozin did not affect the change in LVESVI from baseline to 24 weeks (between-group difference = 0.3 ml/m2, 95% confidence interval -5.2 to 5.8; p = 0.92). Compared with placebo, empagliflozin also had no effect on LVEDVI, LVEF, left atrial volume index, left ventricular mass index, NT-proBNP, or hs-TnI, but did increase haematocrit and reduced uric acid and weight. In patients with left ventricular systolic dysfunction after an acute MI receiving contemporary standard of care, treatment with empagliflozin had no effect on cardiac volumes or LVEF compared with placebo. Progressive adverse cardiac remodelling did not occur in the majority of patients.

Biatrial and Biventricular Reference Ranges Based on Cardiac Magnetic Resonance in Sickle Cell Disease Patients Without Heart Damage.

We aimed to establish biatrial and biventricular reference ranges using cardiac magnetic resonance (CMR) parameters in SCD patients without heart damage. This study compared CMR parameters, quantified by cine SSFP sequences, in 48 adult SCD patients without apparent cardiac involvement (defined by the absence of known risk factors, normal electrocardiogram, and no macroscopic myocardial fibrosis or significant cardiac iron on T2* CMR) to matched cohorts of 96 healthy controls and 96 thalassemia major (TM) patients without cardiac damage. Nine paediatric SCD patients were also analysed and compared to age- and gender-matched groups of nine TM patients and nine healthy subjects. In all groups, studied males displayed higher biventricular volumes and mass indexes than females. Male SCD patients showed significantly higher left ventricular (LV) end-diastolic volume index (EDVI), LV end-systolic volume index (ESVI), LV stroke volume index (SVI), cardiac index, LV and right ventricular (RV) mass index, and atrial areas than healthy subjects. Females with SCD exhibited increased LV EDVI, LV SVI, RV mass index, and left atrial area index compared to healthy controls. SCD and TM patients showed comparable biatrial areas and biventricular volumes and function. When compared to TM, SCD males exhibited a larger mass index, while SCD females showed an increased RV mass index. CMR parameters were similar across all paediatric groups. By establishing the biatrial and biventricular reference ranges through CMR for adult male and female SCD patients, we aimed to prevent possible misdiagnosis of cardiomyopathy in this population by taking into account cardiac adaptation due to anaemia.

Five-Year Comparison Results Between Clinically Severely Affected Tetralogy-of-Fallot Patients Initially Treated by Right Ventricular Outflow Stenting and Pink-Fallot Patients Undergoing Single-Step Correction.

Evaluation of the short-term and long-term results of a phased correction of the tetralogy of Fallot (ToF) with stenting of the right ventricular outflow tract (RVOT) in comparison with a one-stage total correction (TC) of the defect. Two groups of patients with classical ToF were formed. Group 1 (n = 25; median age = 72 days) was initially represented by children with ToF with a more severe clinical status (median weight = 3.6 kg, with more pronounced cyanosis and with comorbidities). The children of group 1 underwent the first stage of RVOT stenting and the second stage of TC of ToF. Group 2 (n = 25) was represented by older patients, with a higher body weight and SpO2 level, and they underwent a single-stage TC of the defect. The application of a step-by-step ToF correction approach with RVOT stenting in low-weight newborns with severe hypoxemia demonstrated an equivalent effect on SpO2 dynamics-reverse remodeling of the heart-when compared with a less severe cohort of patients who underwent simultaneous TC of classical ToF. After RVOT stenting in children from group 1, the median SpO2 increased from 80% to 94.5%, the median Z value of the pulmonary artery trunk decreased from -3.46 mm to -2.54 mm, and the median index of end-diastolic volume of the left ventricle decreased from 23.07 mm/m2 to 57.6 mL/m2. TC of ToF in children from group 1 with a phased strategy of correction of the defect was no less successful than in children who underwent simultaneous TC. In the long-term follow-up period after TC of ToF, children from both groups, who were obviously unequal in their initial status, were practically comparable in clinical characteristics, exhibiting features of cardiac remodeling and achieving endpoints. And there were no significant differences between the two groups in the frequency of reaching the endpoints such as re-operations, cerebrovascular events, and death during the annual, three-year, and five-year follow-up period. The strategy of RVOT stenting followed by TC of ToF in a severe group of children demonstrated comparable results compared with the results of simultaneous TC of ToF in a more stable group of patients during the in-hospital, annual, three-year, and five-year follow-up periods.

Pulsatile Vascular Afterload Measurement Improves Prediction of Right-Sided Heart Dysfunction in Undifferentiated and Left-Sided Pulmonary Hypertension.

The association between raised pulmonary artery pressures, pulmonary vascular resistance (PVR), and right-sided heart dysfunction is well recognized. The added value of pulsatile indices, specifically pulmonary arterial compliance (PAC) and characteristic impedance, remains unclear. This study aimed to identify the optimal vascular afterload model for predicting right-sided heart dysfunction in newly diagnosed pulmonary hypertension (PH). This was a prospective cohort study of 86 patients with suspected PH (60±16 years; 66 women) who underwent right-sided heart catheterization and cardiac magnetic resonance imaging. Right ventricular end-diastolic volume index (RVEDVi) and right atrial (RA) volume index were measured using cardiac magnetic resonance imaging. Vascular resistance, PAC, and characteristic impedance were measured using pulmonary artery pressure from right-sided heart catheterization and pulmonary artery flow from cardiac magnetic resonance imaging. Optimal model fit was determined by the lowest Akaike Information Criterion value. A total of 58% of patients had a right ventricular ejection fraction <50%, 63% had an increased RVEDVi, and 56% had an increased RA volume index. Overall, PVR was the best predictor of right ventricular ejection fraction <50% (P<0.01), increased RVEDVi (P<0.01), and RA volume index (P=0.02). However, for patients with a PVR <240 dynes.s.cm-5, PACclinical outperformed PVR in predicting right ventricular ejection fraction <50% (P=0.02) and increased RVEDVi (P=0.05). A 3-component model (PVR, PACclinical, and characteristic impedance) best predicted RA dilatation (P=0.05). In paired analysis, alternative methods of PAC quantification better predicted increased RVEDVi (PACdecay P=0.02) and RA volume index (PACarea P=0.02). PACclinical <2.3 mL/mm Hg optimally predicted right-sided heart dysfunction (area under the curve, 0.768) and increased the AUC for PVR in undifferentiated/left-sided PH (0.89 versus 0.72). Pulsatile vascular afterload measurement improves right-sided heart dysfunction prediction in undifferentiated/left-sided PH. More accurate PAC measurement methods could further enhance prognostic accuracy, while a PVR ≥240 dynes.s.cm-5 remains a valuable threshold for precapillary PH.

Wide variation in shape of hypoplastic left ventricles undergoing recruitment and biventricular repair: A statistical shape modeling study.

Patients with hypoplastic left ventricles (LV) who undergo volume-loading procedures (recruitment, biventricular [BIV] repair) are at risk for adverse outcomes, including heart failure and death. We investigated pre-BIV LV shape as a predictor of outcome after BIV repair in patients with hypoplastic LVs. Baseline and post-recruitment cardiac magnetic resonance imaging and computed tomography data were analyzed in patients with hypoplastic LV (<50mL/m2). Statistical shape modeling (SSM) was utilized to generate a model of the shape and variability of LVs. Traditional measures of LV sphericity and eccentricity were also measured. Major adverse cardiovascular events (MACE) included heart failure, transplant, and death. Of 95 patients with baseline mean LV volume 29±13mL/m2, 45/95 (47%) had a right dominant atrioventricular canal defect, 31/95 (33%) had a variant of hypoplastic left heart syndrome, and 18/95 (19%) had endocardial fibroelastosis (EFE). A wide variation in LV shape was found by SSM, and shape modes were associated with right ventricle (RV) and LV size, and diagnosis. BIV repair was achieved in 74/95 (78%) patients; 13/74 (18%) of BIV patients had MACE. Predictors of MACE following BIV repair included EFE, higher RV mass index, and higher RV end-diastolic volume index. No baseline or post-recruitment LV shape parameter was associated with the outcome after BIV repair. The shape model of hypoplastic LVs demonstrated a wide array of LV shapes. LVs gained sphericity and size and lost eccentricity with recruitment. Though the ventricles changed shape with recruitment, no specific LV shape characteristic at the baseline or post-recruitment stage was predictive of decision to proceed with BIV repair or outcome. Higher RV mass and volume may represent new biomarkers that predict outcomes following BIV repair in patients with hypoplastic LV. Further investigation could determine the reproducibility of these findings.

Laboratory and instrumental parameters associated with the risk of death in the long-term follow-up period in patients after myocardial infarction

BACKGROUND: In patients who successfully survived the 1st year after myocardial infarction, the risk of death remains elevated. AIM: To determine laboratory and instrumental parameters of myocardial remodeling associated with a lethal outcome in the long-term follow-up period in patients 1 year after myocardial infarction. MATERIAL AND METHODS: The study included 184 patients 12 months after myocardial infarction: the first group — living patients at the 5-year follow-up point (n=160), the second group — deceased patients at the 5-year follow-up point (n=24). A comparative analysis of inflammation and myocardial dysfunction biomarkers, as well as echocardiographic parameters reflecting the types of left ventricular remodeling, linear dimensions of the cavities and wall thickness of the heart, chamber volumes, and ventricular systolic function was retrospectively performed. After assessing the distribution of quantitative data, the Student's t-test or Mann–Whitney U-test and the χ2 criterion for categorical data were used. The model was built on the basis of logistic regression. The ROC curve, the Hosmer–Lemeshow test, and the bootstrap method were used to assess the model itself and its reliability. RESULTS: Patients in the second group were older (p=0.007), and more often had myocardial infarction with ST-segment elevation during hospitalization (p 0.001). Twelve months after myocardial infarction, a multidirectional pattern of changes in the level of N-terminal brain natriuretic propeptide was revealed: a decrease was registered in the first group, while an increase was registered in the second group. In the dynamics of the second group, the index of end-diastolic volume (p=0.014) and the size of left ventricular asynergy were higher (p=0.043), and the ejection fraction was lower (p=0.015) than in the first group. The model for predicting 4-year mortality in patients who survived myocardial infarction during the 1st year included such parameters as the index of the left ventricular end-diastolic volume, the content of the N-terminal fragment of the natriuretic peptide and the presence of concentric hypertrophy of the left ventricle. CONCLUSION: In patients who survived 1 year after myocardial infarction, the long-term risk of death is associated with a set of parameters reflecting left ventricular remodeling and the development of heart failure.

Study on predicting new onset heart failure events in patients with hypertrophic cardiomyopathy using machine learning algorithms based on clinical and magnetic resonance features

Objective: To explore the value of predicting new-onset heart failure events in patients with hypertrophic cardiomyopathy (HCM) using clinical and cardiac magnetic resonance (CMR) features based on machine learning algorithms. Methods: The study was a retrospective cohort study. Patients with a confirmed diagnosis of HCM who underwent CMR examinations at Beijing Anzhen Hospital from May 2017 to March 2021 were selected and randomly divided into the training set and the validation set in a ratio of 7∶3. Clinical data and CMR parameters (including conventional parameters and radiomics features) were collected. The endpoint events were heart failure hospitalization and heart failure death, with follow-up ending in January 2023. Features with high stability and P value<0.05 in univariate Cox regression analysis were selected. Subsequently, three machine learning algorithms-random forest, decision tree, and XGBoost-were used to build heart failure event prediction models in the training set. The model performance was then evaluated using the independent validation set, with the performance assessed based on the concordance index. Results: A total of 462 patients were included, with a median age of 51 (39, 62) years, of whom 332 (71.9%) were male. There were 323 patients in the training set and 139 in the validation set. The median follow-up time was 42 (28, 52) months. A total of 44 patients (9.5% (44/462)) experienced endpoint events (8 cases of heart failure death and 36 cases of heart failure hospitalization), with 31 events in the training set and 13 in the validation set. Univariate Cox regression analysis identified 39 radiomic features, 4 conventional CMR parameters (left ventricular end-diastolic volume index, left ventricular end-systolic volume index, left ventricular ejection fraction, and late gadolinium enhancement ratio), and 1 clinical feature (history of non-sustained ventricular tachycardia) that could be included in the machine learning model. In the prediction models built with the training set, the concordance indices for the random forest, decision tree, and XGBoost models were 0.966 (95%CI 0.813-0.995), 0.956 (95%CI 0.796-0.992), and 0.973 (95%CI 0.823-0.996), respectively. In the validation set, the concordance indices for the random forest, decision tree, and XGBoost models were 0.854 (95%CI 0.557-0.964), 0.706 (95%CI 0.399-0.896), and 0.703 (95%CI 0.408-0.890), respectively. Conclusion: Integrating clinical and CMR features of HCM patients through machine learning aids in predicting heart failure events, with the random forest model showing superior performance.

Comparing HeartModelAI and cardiac magnetic resonance imaging for left ventricular volume and function evaluation in patients with dilated cardiomyopathy

BackgroundIntegration of artificial intelligence enhances precision, yielding dependable evaluations of left ventricular volumes and ejection fraction despite image quality variations. Commercial software like HeartModelAI provides fully automated 3DE quantification, simplifying the measurement of left chamber volumes and ejection fraction. In this manuscript, we present a cross-sectional study to assess and compare the diagnostic accuracy of automated 3D echocardiography (HeartModelAI) to the standard Cardiac Magnetic Resonance Imaging in patients with dilated cardiomyopathy.MethodsIn this cross-sectional study, 30 patients with dilated cardiomyopathy referring to the Tehran Heart Center with cardiac magnetic resonance imaging and comprehensive 3D transthoracic echocardiography within 24 h were included. All 3D volume analysis was performed with fully automated quantification software (HeartModelAI) using 3D images of 2,3, and 4-chamber views at the end of systole and diastole.ResultsExcellent Inter- and Intra-observer correlation coefficient was reported for HeartModelAI software for all indexes. HeartModelAI displayed a remarkable correlation with cardiac magnetic resonance for left ventricular end-systolic volume index (r = 0.918 and r = 0.911); nevertheless, it underestimated left ventricular end-systolic volume index and left ventricular end-diastolic volume index. Conversely, ejection fraction, stroke volume, and left ventricular mass were overestimated. It was found that manual contour correction can enhance the accuracy of automated model estimations, particularly concerning EF in participants needing correction.ConclusionHeartModelAI software emerges as a rapid and viable imaging approach for evaluating the left ventricle’s structure and function. In our study, LV volumes assessed by HeartModelAI demonstrated strong correlations with cardiac magnetic resonance imaging.

Correlating Electrocardiograms with Echocardiographic Parameters in Hemodynamically-Significant Aortic Regurgitation Using Deep Learning.

Of all electrocardiogram (ECG) deep-learning (DL) models used to detect left-sided valvular heart diseases, aortic regurgitation (AR) has been the hardest to detect. Moreover, to what extent ECGs could detect AR-related left ventricular (LV) remodeling and dysfunction is unknown. We aimed to evaluate the ability of DL-based ECG models to predict LV remodeling parameters associated with hemodynamically significant AR. From 573 consecutive patients, 1457 12-lead ECGs close to baseline transthoracic echocardiograms confirming ≥ moderate-severe AR and before aortic valve surgery were retrospectively collected. A ResNet-based model was used to predict LV ejection fraction (LVEF), LV end-diastolic dimension (LVEDD), LV end-systolic dimension index (LVESDi), LV mass index (LVMi), LV end-diastolic volume index (LVEDVi), LV end-systolic volume index (LVESVi), and bicuspid aortic valve (BAV) from the ECGs. Five-fold cross-validation was used for model development (80%) with the held-out testing set (20%) to evaluate its performance. Our DL model achieved area under receiver operating characteristic curves (AUROCs) of 0.77, 0.80, and 0.87 for discriminating LVEF < 55%, < 50%, and < 40%. For LVEDD > 65 mm, LVESDi > 30 mm/m2, LVESVi > 45 ml/m2, LVEDVi > 99 ml/m2, LVMi > 158 mm/m2, and BAV, our model also achieved significant results, with AUROCs of 0.83, 0.85, 0.84, 0.81, 0.78, and 0.74, respectively. The SHapley Additive exPlanation values showed that our model focused on the QRS complex while making decisions. Our DL model found correlations between ECGs and parameters indicating LV remodeling and dysfunction in patients with significant AR. Analyzing ECGs with DL models may assist in the timely detection of LV dysfunction and screening for the necessity of additional echocardiography exams, especially when echocardiography might not be readily available.

Echocardiographic Evaluation of Chronic Aortic Regurgitation: Comparison With Cardiac Magnetic Resonance and Implications for Guideline Recommendations.

Guidelines for echocardiographic evaluation of aortic regurgitation (AR) have not been validated against an independent quantitative standard. The aim of this study was to evaluate the accuracy of the ASE (American Society of Echocardiography) AR guidelines against cardiac magnetic resonance (CMR) and to develop simplified approaches for detection of significant AR. Patients with AR underwent echocardiography and CMR<4 hours apart. AR severity was graded according to ASE guidelines. Quantitation of regurgitant volume (RegV) was performed with pulsed Doppler at the mitral annulus and right ventricular outflow compared with left ventricular (LV) outflow, and with proximal isovelocity surface area. The authors studied 81 patients; median age was 52 years, and 58% had a bicuspid aortic valve. According to echo, 35 (43%) patients had mild AR, 18 (22%) moderate, 12 (15%) moderate to severe, and 16 (20%) had severe AR. The area under the curve (AUC) for detection of severe AR by CMR using ASE grading was 0.9 (82.4% sensitivity and 96.9% specificity). Feasibility of RegV quantitation was >88% using either echo volumetric method, and it was low for proximal isovelocity surface area (37%). The highest accuracy for echo parameters against CMR was seen with vena contracta width, jet width, and LV end-diastolic volume index (AUC: 0.86-0.89); pressure half-time had the lowest accuracy. Without RegV quantitation, a vena contracta width≥0.5cm and indexed LV end-diastolic volume≥82mL/m2 had 95.5% positive predictive value and 87.5% negative predictive value for identifying≥moderate to severe AR by CMR (AUC: 0.89). The ASE guidelines display very good performance in identifying significant AR. A simplified approach using vena contracta width and LV volumes can be used to reliably identify significant AR. Further validation of the findings in larger cohorts and against clinical outcomes is needed.

Cardiovascular magnetic resonance semi-automated threshold-based post-processing of right ventricular volumes in repaired tetralogy of Fallot.

Cardiovascular magnetic resonance (CMR) is the gold-standard to estimate right ventricular (RV) volumes, which are key for clinical management of patients with repaired tetralogy of Fallot (rTOF). Semi-automated threshold-based methods (SAT) have been proposed for CMR post-processing as alternatives to fully manual standard tracing. We investigated the impact of SAT on RV analysis using different thresholds in rTOF patients. RV volumes and mass were estimated using SAT and standard fully manual tracing methods in rTOF patients. Two threshold levels were set for SAT, i.e., default 50 (SAT-50) and 30 (SAT-30). RV stroke volumes (SV) were compared to main pulmonary artery forward flow (MPA-FF). Post-processing time, intra- and interobserver variabilities were compared across methods. Sixty-two CMRs of rTOF patients were analyzed. Compared to the standard fully manual tracing, no significant differences in RV mass, volumes and ejection fraction were observed using SAT-30, whereas SAT-50 significantly underestimated RV end-diastolic-volume index (EDVi) by 10.4% (mean difference of - 11.8 ± 6.2ml/m2, p 0.03) and overestimated RV mass index by 21.8% (mean difference of 14.2 ± 11.9g/m2, p 0.002). Compared to MPA-FF, RVSV by standardfully manual method and SAT-30 showed minor biases, respectively, 0.03ml/m2 and 0.7ml/m2, while SAT-50 underestimated RVSV by 6.86ml/m2 (p < 0.001). In six patients, the degree of RV EDVi underestimation by SAT-50 determined a change of category from dilated to non-dilated RV. Intra- and interobserver variabilities were good to excellent for all methods. Post-processing duration was shorter for SAT compared to standardmanual segmentation (5.5 ± 1.7min vs. 19.5 ± 4.4min, p < 0.001). CMR SAT-30 post-processing is a precise, accurate and time-saving method for biventricular assessment of volumes, ejection fraction and mass in rTOF.

Evaluating Impact of Surgical Myocardial Revascularization on Global Left Ventricular Systolic Function and Immediate Postoperative Outcome using Transesophageal Echocardiography

Abstract Background and Aims: Surgical myocardial revascularization is supposed to improve the global left ventricular (LV) function by improving the blood supply in significantly occluded coronary arteries. Transesophageal echocardiography (TEE) provides an excellent opportunity to evaluate cardiac function in operating room. Present study was aimed at evaluating impact of surgical myocardial revascularization on global LV systolic function. Comparison of LV fractional shortening (LV-FS), fractional area change (LV-FAC), ejection fraction (LV-EF), indexed LV volumes (indexed LV volumes at end diastole, LV volumes at end systole) and “Tei” (Myocardial performance) index obtained prior and after surgical myocardial revascularization was done for quantitative analysis. Also, the determinants of immediate postoperative outcome were evaluated based on need of pharmacological and/or mechanical cardiovascular support, mechanical ventilation, intensive care unit (ICU) stay, morbidity and mortality in immediate postoperative period. These outcome measures were correlated with baseline values of TEE derived echo indices. Methods: One hundred and ten subjects with significant coronary artery disease scheduled for elective myocardial revascularization surgery. Fourteen subjects were excluded due to presence of either hemodynamic instability requiring either pharmacological or mechanical cardiovascular support, before coronary revascularization (n = 6), presence of Grade III mitral regurgitation (MR) in baseline TEE (n = 2) and arrythmias (n = 6). Ninety six subjects were evaluated for global LV systolic function using TEE before and after surgical revascularization. Subjects were followed in ICU for the outcome. Immediate postoperative outcome was measured as “good” or “poor” based on vasoactive inotropic score, requirement of Intra-aortic balloon counter pulsation (IABP) and mechanical cardiovascular support (VA-ECMO) to maintain cardiac output, duration of mechanical ventilation, postoperative ICU stay, morbidity and mortality. Results: In 96 subjects analyzed, there was a significant improvement in TEE derived LV-FS (38.60 ± 16.38 vs. 31.31 ± 13.14) (P = 0.002), FAC (51.94 ± 16.06 vs. 43.99 ± 16.02) (P ≤ 0.001), EF (53.08 ± 9.97 vs. 46.71 ± 7.53) (P &lt; 0.00001), LV end diastolic volume index (34.84 ± 13.43 vs. 40.08 ± 17.22) (P = 0.0188) and “Tei” index (0.47 ± 0.13 vs. 0.53 ± 0.13) (P = 0.0007). Thirty three subjects required either prolonged stay in ICU (&gt;7 days), (n = 20) and/or mechanical ventilatory support (&gt;24 h), (n = 10) and/or mechanical cardiovascular support (IABP/VA ECMO placement), (n = 7) and/or suffered mortality (n = 2) in postoperative period were categorized as “poor” outcome. Presence of type II diabetes mellitus, Chronic obstructive pulmonary disease (COPD), higher grade of ischemic MR, larger LV end diastolic volume, use of cardiopulmonary bypass and allogenic blood transfusion during surgery were the determinants of “poor” outcome. Conclusion: Surgical myocardial revascularization improved global LV systolic function irrespective of baseline LV EF. Immediate postoperative outcome was strongly determined by presence of diabetes, COPD, higher grade of ischemic MR and larger LV end diastolic volumes. Preoperative (Baseline) LV EF and myocardial performance index did not determine “poor” postoperative outcome following surgical myocardial revascularization in subjects with LVEF &gt;35%.

The correlation between cardiac magnetic resonance imaging and echocardiography in patients with severe ischaemic cardiomyopathy

Abstract Background Left ventricular ejection fraction is the single metric that guides therapeutic decision-making, risk stratification and prognosis in patients with severely impaired systolic function. Although cardiac magnetic resonance imaging (CMR) is the current reference standard for quantification of ventricular volume and function, echocardiography is used more often as it is more widely available and less expensive.(1) Aims To evaluate the correlation between CMR and echocardiography in quantifying left ventricular (LV) volume and function and to determine whether these measurements are associated with clinical outcomes in patients with severe ischemic cardiomyopathy (ICM). Methods Participants recruited to the REVIVED-BCIS2 trial who had undergone baseline CMR or echocardiography were included in this analysis. All scans were analyzed in blinded core laboratories as previously reported.(2,3) All volumes were indexed to body surface area. Spearman correlation, Bland Altman analysis and coverage probability methods were performed to assess the correlation between the two modalities. A Cox proportional hazards model was used to assess the association between imaging metrics and the primary outcome, a composite of all-cause death and aborted sudden death. A sensitivity analysis was conducted a priori, restricted to patients undergoing both scans within 60 days of each other. Results A total of 373 participants with paired imaging data were included: mean age 69±9 years, 87% male, BMI 28±5. A moderate correlation was detected for volume measurements between the modalities (end diastolic volume index (EDVI) r=0.66 end systolic volume index (ESVI) r=0.68), with a weaker correlation for LV ejection fraction (EF) (r=0.41). Bland-Altman plots showed moderate agreement in LVEF measurements (Table 1). The sensitivity analysis included 199 patients, and showed similar results (EDVI r=0.72, ESVI r=0.73 LVEF r=0.43, all p&amp;lt;0.000). Only 7.5% of the paired LVEF measurements were within 5% of each other. 30% of participants were misclassified by echocardiography as having an LVEF&amp;gt;35%. (Figure 1) CMR ESVI was associated with the occurrence of the primary outcome (HR 1.05 per 10ml increment, 95% CI 1.00-1.10) however echo ESVI (HR 1.05 per 10ml increment 95% CI 0.99 – 1.10) and all other imaging metrics were not. Conclusion Left ventricular volumes and ejection fraction on CMR and echocardiography were only modestly correlated in this population with severe ICM. When using the binary EF threshold of 35% that is commonly used to select patients of implantable defibrillator therapy, almost a third of patients at risk would have been missed by echocardiography alone. The additional insights provided by CMR, including scar burden, further support preferential use of this modality in the assessment such patients.

Prognostic yield of echocardiographic measures of cardiac structure and function in HFrEF patients with vs without an ICD or CRT-D

Abstract Background Selected echocardiographic measures of cardiac structure and function are known to be associated with mortality in patients with Heart Failure with reduced Left Ventricular (LV) Ejection Fraction (HFrEF). Whether the predictive ability of measures of cardiac structure and function remain after implantation of an Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) is unknown among patients with HFrEF. Purpose To compare the predictive ability of echocardiographic measures of cardiac structure and function in HFrEF patients with or without an ICD/CRT-D. Methods Echocardiographic examinations were performed between 2003 and 2013 and retrieved from 2168 patients with HFrEF. Patients that had an ICD or CRT-D implanted during follow-up were identified through registries. The endpoint was all-cause mortality and follow-up was 100% to date. Images were analyzed offline in accordance with current guidelines. Associations were assessed by Cox multivariable regression and Cox univariable interaction models. Results After a median of 169 days, 677 patients had an ICD or CRT-D implanted. In total, 68% vs 80% of patients with and without an ICD, respectively, were men (p&amp;lt;0.001) and the median age were 70 vs 71 years (p=0.192). There was a significant difference in resting heart rate (median 74 vs 69, p&amp;lt;0.001) and frequency of ischemic heart disease (64% vs 81%, p&amp;lt;0.001) between the groups. Patients with an ICD had a higher mortality rate (69 per 1000 people/year vs 92 per 1000 people/year, p&amp;lt;0.001) and died significantly faster (median 9.3 vs 8.2 years, p&amp;lt;0.001). Patients with an ICD had higher Left Atrial (LA) End Systolic Volume (59.2 vs 67.3, p&amp;lt;0.001), LA Volume Index (28.5 vs 33.9, p&amp;lt;0.001), LV End Diastolic Volume (137.7 vs 153.7, p&amp;lt;0.001), and LV Mass Index (114.5 vs 124.5, p&amp;lt;0.001), as well as lower LA strain (9.8 vs 6.3, p&amp;lt;0.001) and TAPSE (2.0 vs 1.7, p&amp;lt;0.001). In patients without an ICD, Right Ventricular strain was associated with mortality (HR = 1.05 per 1% decrease mm/m2 [1.005, 1.11] when adjusting for covariates whereas in patients with an ICD, LA Volume Index (HR 1.14 per 1 increase [1.03, 1.25], and LV Ejection Fraction (HR 0.96 per 1% increase [0.92, 0.99]) were associated with mortality when adjusting for covariates. ICD/CRT-D implantation significantly modified the prognostic yield of LV End Diastolic Volume (HR per 1 ml increase: 0.99 without vs 1.01 with an ICD/CRT-D, p=0.005) and LV Mass Index (HR per 1 g/m2 increase: 1.00 without and 1.01 with an ICD/CRT-D, p=0.031). Conclusion Different echocardiographic measures were stronger prognosticators in HFrEF patients with and without an ICD or CRT-D, respectively, and ICD implantation modified the prognostic yield of LV End Diastolic Volume and LV Mass Index in HFrEF patients.Table 1Forest plot

Early increase and subsequent decrease in mature BNP and early decrease and continued decrease in proBNP after sacubitril/valsartan may relate to left ventricular reverse remodeling in heart failure

Abstract Background Current BNP assays measure not only mature BNP (BNP1-32) but also precursor proBNP. Previous studies have shown that the change in BNP after sacubitril/valsartan (Sac/Val) treatment is not consistent. The reason for this may be due to the fact that the immunoreactivity of BNP consists of mature BNP and proBNP and neprilysin degrades only mature BNP but not proBNP. Purpose This study assessed changes in mature BNP, proBNP, total BNP (= mature BNP + proBNP) before and 2 and 12 weeks after administration of Sac/Val in heart failure (HF). Methods We measured mature BNP, proBNP, and total BNP levels by our developed immunoassay, NT-proBNP and ANP by conventional assay and left ventricular (LV) remodeling indices by echocargdioraphy in 34 HF patients before, 2, and 12 weeks (wk) after Sac/Val treatment. 34 HF patients were divided into two groups. Group D (n=20) was defined as the group whose mature BNP at 12wk was lower than the baseline. Whereas Group I (n=14) was defined as the group whose mature BNP at 12wk was higher than the baseline. Results In all patients, total BNP did not change after 2wk or 12wk compared to baseline. ProBNP decreased after 2wk and tended to decrease after 12wk (p=0.07). Whereas there was no change inmature BNP after 2wk or 12wk (Table 1). In group D, total BNP did not change at 2wk, but decreased after 12wk. Mature BNP did not change at 2wk, but decreased after 12wk. ProBNP decreased at 2wk and further decreased at 12wk. In contrast, in group I total BNP did not change at 2wk, but increased at 12wk. ProBNP did not change after 2wk or 12wk compared to baseline. Mature BNP increased after 2wk and further increased after 12wk. Thus, a decrease in both proBNP and mature BNP contributed to the decrease in total BNP in group D, while the increase in total BNP in group I was mainly due to the increase in mature BNP. Correlation coefficient and p value between total BNP, proBNP, mature BNP, NT-proBNP and ANP at baseline, 2wk and 12wk are shown in Table 2. A close correlation was observed between BNP molecular forms. NT-proBNP decreased and ANP increased after Sac/Val administration; however, there was a modest correlation between the two peptides. There were no significant differences in LV ejection fraction (LVEF: %), end-diastolic volume index (LVEDVI: ml/m²) or end-systolic volume index (LVESVI: ml/m²) between two groups at baseline or at 12 wk; however, the delta (at 12 wk – pretreatment) LVEDVI, and LVESVI significantly improved in group D compared with group I (-9.3±11.3 vs. 3.7±10.1, p&amp;lt;0.01; -8.2±13.5 vs. 2.7±8.9, p&amp;lt;0.01, respectively). Conclusion These results suggest that total BNP appears to be unchanged after Sac/Val administration, but its components, proBNP and mature BNP, are altered; reverse cardiac remodeling may relate to decrease of mature BNP and proBNP; and the closely correlated natriuretic peptide molecules, regardless of the degradation by neprilysin, may be regulated in the same direction.